Surgery alone for advanced prostate cancer?

European Journal of Cancer, Supplement

Volumn 5, Issue 5, 2007, Pages 157-169

  Van Poppel, Hendrik ^a   Joniau, Steven ^a   Haustermans, Karin ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANEMIA; ARTICLE; BODY FAT; BONE METASTASIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; COGNITIVE DEFECT; DEPRESSION; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLIC DISORDER; MUSCLE ATROPHY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT;

EID: 35548939036     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70036-8     Document Type: Article

References (81)

1. Boccon-Gibod L., Bertaccini A., Bono A., et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 57 3 (2003) 187-194
2. th ed. (2002), Wiley. Liss, New York 184-187
3. Aus G., Abbou C., Bolla M., et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 48 4 (2005) 546-551
4. Partin A., Mangold L., Lamm D., Walsh P., Epstein J., and Pearson J. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millenium. Urology 58 (2001) 615-619
5. Nakashima J., Tanimoto A., Imai Y., et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 64 1 (2004) 101-105
6. Vallancien G., Bochereau G., Wetzel O., Bretheau D., Prapotnich D., and Bougaran J. Influence of preoperative positive seminal vesicle biopsy on the staging of prostatic cancer. J Urol 152 4 (1994) 1168-1169
7. Amling C., Leibovich B., Lerner S., et al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 15 4 (1997) 215-221
8. Gerber G., Thisted R., Chodak G., et al. Results of Radical prostatectomy in men with locally advanced prostate cancer: multi-institution pooled analysis. Eur Urol 32 (1997) 385-390
9. Martinez de la Riva S., Lopez-Tomasety J., Dominguez R., Cruz E., and Blanco P. Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 57 7 (2004) 679-692
10. Ward J., Slezak J., Blute M., Bergstralh E., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 6 (2005) 751-756
11. Hsu C., Joniau S., Oyen R., Roskams T., and Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 1 (2007) 121-128 discussion 128-129.
12. Swanson G., Riggs M., and Earle J. Long-term follow-up of radiotherapy for prostate cancer. Int J of Rad Onc Biol Phys 59 2 (2004) 406-411
13. Hahn P., Baral E., Cheang M., Math M., Kostyra J., and Roelss R. Long-term outcome of radical radiation therapy for prostatic carcinoma: 1967-1987. Int J Radiat Oncol Biol Phys 34 1 (1996) 41-47
14. Ennis R., and Peschel R. Radiation therapy for prostate cancer. Long-term results and implications for future advances. Cancer 72 9 (1993) 2644-2650
15. Zagars G., Pollack A., and Smith L. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, Nx/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 44 4 (1999) 809-819
16. O'Connor K., and Fitzpatrick J. Side-effects of treatments for locally advanced prostate cancer. BJU Int 97 1 (2006) 22-28
17. Swanson G. Management of locally advanced prostate cancer: past, present, future. J Urol 176 6 Pt 2 (2006) S34-S41
18. Kumar R., Barqawi A., and Crawford E. Preventing and treating the complications of hormone therapy. Curr Urol Rep 6 3 (2005) 217-223
19. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 9327 (2002) 103-106
20. Laverdiere J., Gomez J., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 2 (1997) 247-252
21. Pilepich M., Winter K., John M., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 5 (2001) 1243-1252
22. Lawton C., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 4 (2001) 937-946
23. Hanks G., Pajak T., Porter A., et al. Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 21 (2003) 3972-3978 Erratum in:
24. J Clin Oncol 22 2 (2004) 386
25. Pilepich M., Winter K., Lawton C., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma -long- term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 5 (2005) 1285-1290
26. Roach III M., DeSilvio M., Lawton C., et al. Radiation Therapy Oncology Group 9413. Phase III trial comparing whole- pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 10 (2003) 1904-1911
27. Ward J., and Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep 4 3 (2003) 196-204
28. McLeod D., Iversen P., See W., Morris T., Armstrong J., Wirth M., and Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 2 (2006) 247-254
29. Van Poppel H., Goethuys H., Callewaert P., Vanuytsel L., Van de Voorde W., and Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 38 (2000) 372-379
30. Hsu C., Joniau S., and Van Poppel H. Radical prostatectomy for locally advanced prostate cancer: technical aspects of radical prostatectomy. EAU Update Series 3 (2005) 90-97
31. Van Poppel H. Surgery for clinical T3 prostate cancer. Eur Urol, Suppl 4 (2005) 2-14
32. Hsu C., Joniau S., Roskams T., Oyen R., and Van Poppel H. Comparing results after surgery in patients with clinical unilateral T3a, prostate cancer treated with or without neoadjuvant androgen-deprivation therapy. BJU Int 99 (2006) 311-314
33. Van Poppel H., Ameye F., Oyen R., Van de Voorde W., and Baert L. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 151 5 (1994) 1310-1314
34. Lepor H., Nieder A., and Ferrandino M. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol 166 (2001) 1729-1733
35. Augustin H., Hammerer P., Graefen M., et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single centre between 1999 and 2002. Eur Urol 43 (2003) 113-118
36. Maffezzini M., Seveso M., Taverna G., Giusti G., Benetti A., and Graziotti P. Evaluation of complications and results in a contemporary series of 300 consecutive radical retropubic prostatectomies with the anatomic approach at a single institution. Urology 61 (2003) 982-986
37. Joniau S., Hsu C., Lerut E., et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral t3a prostate cancer. Eur Urol 51 2 (2007) 388-396
38. Hsu C., Joniau S., Oyen R., Roskams T., and Van Poppel H. Transrectal ultrasound in the staging of clinical T3a prostate cancer. Eur J Surg Oncol 33 1 (2007) 79-82
39. Gontero P., Marchioro G., Pisani R., et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol (2006) [Epub ahead of print].
40. Yamada A., Lieskovsky G., Petrovich Z., et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 17 (1994) 277-285
41. van den Ouden D., Hop W., and Schroder F. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160 4 (1998) 1392-1397
42. van den Ouden D., and Schroder F. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. WorldJ Urol 18 3 (2000) 194-203
43. Van Poppel H., Vekemans K., Da Pozzo L., et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 42 8 (2006) 1062-1067
44. Berglund R., Jones J., Ulchaker J., et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 67 6 (2006) 1253-1256
45. Secin F., Bianco Jr. F., Vickers A., et al. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer 106 11 (2006) 2369-2375
46. Masterson T., Pettus J., Middleton R., and Stephenson R. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status. Urology 66 1 (2005) 152-155
47. Johnstone P., Ward K., Goodman M., Assikis V., and Petros J. Radical prostatectomy for clinical T4 prostate cancer. Cancer 106 12 (2006) 2603-2609
48. Carver B., Bianco Jr. F., Scardino P., and Eastham J. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176 2 (2006) 564-568
49. Labrie F., Cusan L., Gomez J.-L., et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomised trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urol Symp 44 6A (1994) 29-37
50. Van Poppel H., De Ridder D., Elgamal A., et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomised trial. The Belgian Uro-Oncological Study Group. J Urol 154 (1995) 429-434
51. Soloway M., Sharifi R., Wajsman Z., McLeod D., Wood Jr. D., and Puras-Baez A. Randomised prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154 (1995) 424-428
52. Hugosson J., Abrahamsson P., Ahlgren G., et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 29 (1996) 413-419
53. Goldenberg S., Klotz L., Srigley J., et al. Randomised, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 156 (1996) 873-877
54. Witjes W., Schulman C., and Debruyne F. Preliminary results of a prospective randomised study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 49 Suppl. 3A (1997) 65-69
55. Aus G., Abrahamsson P., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy; a 7-year follow-up of a randomised controlled trial. BJU Int 90 (2002) 561-566
56. Soloway M., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 167 (2002) 112-116
57. Schulman C., Debruyne F., Forster G., Selvaggi F., Zlotta A., and Witjes W. 4-year follow-up results of a European prospective randomised study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-T3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38 (2000) 706-713
58. Van Poppel H., Goethuys H., De Ridder D., et al. Neoadjuvant therapy before radical prostatectomy: impact on progression free survival. Uro-Oncology 1 (2001) 302-307
59. Powell I., Tangen C., Miller G., et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109. J Urol 168 5 (2002) 2016-2019
60. Van Poppel H. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. Eur Urol 39 Suppl. 1 (2001) 10-14
61. Hakenberg O., Frohner M., and Wirth M. Treatment of locally advanced prostate cancer-the case for radical prostatectomy. Urol Int 77 3 (2006) 193-199
62. Lerner S., Blute M., and Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154 4 (1995) 1447-1452
63. Messing E., Manola J., Sarosdy M., Wilding G., Crawford E., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 24 (1999) 1781-1788
64. Kumar S., Shelley M., Harrison C., Coles B., Wilt T., and Mason M. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4 (2006) CD006019
65. Wirth M., Weissbach L., Marx F., et al. Prospective randomised trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45 3 (2004) 267-720 discussion 270.
66. Jacobson G., Smith Jr. J., and Stewart J. Postoperative radiation therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 13 7 (1987) 1021-1024
67. Choo R., Hruby G., Hong J., et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?. Int J Radiat Oncol Biol Phys 52 3 (2002) 674-680
68. Bolla M., Van Poppel H., Collette L., et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 9485 (2005) 572-578 19
69. Thompson Jr. I., Tangen C., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomised clinical trial. JAMA 296 19 (2006) 2329-2335
70. Stephenson A., Shariat S., Zelefsky M., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 11 (2004) 1325-1332
71. Pettaway C., Pisters L., Troncoso P., et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18 5 (2000) 1050-1057
72. Hussain M., Smith D., El-Rayes B., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 61 4 (2003) 774-780
73. Konety B., Eastham J., Reuter V., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 171 2 Pt 1 (2004) 709-713
74. Febbo P., Richie J., George D., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 14 (2005) 5233-5240
75. Dreicer R., Magi-Galluzzi C., Zhou M., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 6 (2004) 1138-1142
76. Akakura K., Suzuki H., Ichikawa T., et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: Results at median follow-up of 102 months. Jpn J Clin Oncol 36 12 (2006) 789-793
77. Roach M., Lu J., Pilepich M., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47 3 (2000) 609-615 Erratum in:
78. Mohuidden M. [corrected to Mohiuddin M]. Int J Radiat Oncol Biol Phys 48 1 (2000) 313
79. Roach M., Lu J., Pilepich M., et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiation Oncol Biol Phys 47 (2000) 617-627
80. Jani A. Management strategies for locally advanced prostate cancer. Drugs Aging 23 2 (2006) 119-129
81. Armstrong A., and Carducci M. New drugs in prostate cancer. Curr Opin Urol 16 3 (2006) 138-145